Assetmark Inc. Acquires 133 Shares of Masimo Co. (NASDAQ:MASI)

Assetmark Inc. boosted its holdings in shares of Masimo Co. (NASDAQ:MASI) by 12.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,183 shares of the medical equipment provider’s stock after purchasing an additional 133 shares during the period. Assetmark Inc.’s holdings in Masimo were worth $158,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. NBC Securities Inc. increased its holdings in shares of Masimo by 47.1% during the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 73 shares in the last quarter. Fifth Third Bancorp increased its holdings in shares of Masimo by 16.4% during the second quarter. Fifth Third Bancorp now owns 695 shares of the medical equipment provider’s stock worth $88,000 after buying an additional 98 shares in the last quarter. Oak Thistle LLC increased its holdings in shares of Masimo by 5.2% during the second quarter. Oak Thistle LLC now owns 2,079 shares of the medical equipment provider’s stock worth $262,000 after buying an additional 103 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Masimo by 75.0% during the second quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock worth $33,000 after buying an additional 111 shares in the last quarter. Finally, HHM Wealth Advisors LLC increased its holdings in shares of Masimo by 25.0% during the second quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock worth $79,000 after buying an additional 125 shares in the last quarter. Institutional investors own 85.96% of the company’s stock.

Wall Street Analyst Weigh In

MASI has been the subject of several recent analyst reports. Piper Sandler raised their price objective on shares of Masimo from $165.00 to $180.00 and gave the stock an “overweight” rating in a report on Wednesday, November 6th. BTIG Research raised their price target on shares of Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a report on Monday, October 14th. Raymond James raised shares of Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 price target for the company in a report on Wednesday, November 6th. Wells Fargo & Company raised their price target on shares of Masimo from $160.00 to $171.00 and gave the company an “overweight” rating in a report on Wednesday, November 6th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Masimo in a report on Wednesday, November 6th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $163.67.

Masimo Trading Up 0.6 %

Masimo stock opened at $161.07 on Monday. The firm has a 50-day moving average of $138.18 and a 200-day moving average of $126.89. Masimo Co. has a one year low of $91.25 and a one year high of $173.90. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The company has a market cap of $8.62 billion, a price-to-earnings ratio of 111.08 and a beta of 0.97.

Masimo (NASDAQ:MASI) last issued its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.84 by $0.14. The company had revenue of $504.60 million for the quarter, compared to analysts’ expectations of $502.87 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. Masimo’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.63 EPS. On average, equities analysts expect that Masimo Co. will post 4.04 earnings per share for the current fiscal year.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.